BPC-157 / KPV (10 mg / 10 mg)

The BPC-157/KPV combination’s pharmacological architecture rests on a two-axis, sequential repair model: KPV operates upstream, suppressing the NF-κB-driven inflammatory cytokine cascade that both causes tissue injury and impairs the repair environment; BPC-157 operates downstream, using the more favorable low-inflammation environment KPV creates to execute cytoprotection, angiogenesis, and structural tissue regeneration more efficiently. The two mechanisms converge at the level of the intestinal epithelium and systemic inflammatory tissue, but through entirely distinct molecular entry points — NF-κB transcriptional inhibition (KPV) versus NO-pathway/growth factor receptor signaling (BPC-157).

Component 1: BPC-157 (Body Protection Compound-157) — 10 mg

BPC-157 is a synthetic pentadecapeptide with the amino acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, developed and extensively characterized by Professor Predrag Sikiric at the University of Zagreb in Croatia. The compound was derived from a portion of the BPC (Body Protection Compound) protein isolated from human gastric juice — a cytoprotective substance naturally present in the stomach — through structure-activity optimization to identify the minimally active sequence retaining full tissue-protective and healing activity. Notably, BPC-157 is stable in gastric juice, allowing oral administration to deliver GI-targeted effects directly to the gut lining — a pharmacologically significant property that enables both injectable and oral routes for GI applications.

Nitric Oxide (NO) Pathway Modulation

BPC-157’s most well-characterized molecular mechanism is upregulation of endothelial nitric oxide synthase (eNOS) expression and activity, with downstream consequences across multiple organ systems:

• Microvascular dilation: eNOS-generated NO induces vasodilation of microvasculature at injury and repair sites, increasing blood flow, oxygen delivery, and nutrient availability to damaged tissue — a prerequisite for effective healing that BPC-157 directly facilitates
• Mucosal vasodilation and gastroprotection: In the gastrointestinal tract specifically, NO-driven mucosal microvascular dilation increases mucosal blood flow and oxygen tension, protecting against ischemia-driven epithelial damage — the primary mechanism underlying BPC-157’s well-documented gastroprotective and ulcer-healing effects
• Prostaglandin upregulation: BPC-157 increases prostaglandin E2 (PGE2) production in GI tissue, reinforcing mucosal cytoprotection through the prostaglandin-dependent pathway that NSAIDs disrupt — explaining the specific evidence for BPC-157’s protective effects against NSAID-induced GI damage
• Platelet aggregation modulation: NO-mediated inhibition of platelet aggregation in microvasculature reduces pathological thrombosis at injury sites while preserving hemostatic function

Growth Factor Receptor Upregulation and Tissue Repair Signaling

• BPC-157 upregulates the expression of EGF (epidermal growth factor) receptor, VEGFR2 (vascular endothelial growth factor receptor 2), and FAK (focal adhesion kinase) at injury sites — amplifying tissue sensitivity to endogenous growth factor signaling without introducing exogenous growth factors, enabling accelerated cellular repair responses
• FAK and paxillin pathway activation: Downstream of VEGFR2 and EGF receptor upregulation, BPC-157 activates focal adhesion kinase and paxillin signaling in fibroblasts, tenocytes, and myocytes — promoting cellular proliferation, migration, and extracellular matrix (ECM) deposition, the cellular mechanics of structural tissue repair
• Egr-1 (early growth response protein 1) pathway: BPC-157 activates the Egr-1 transcription factor, a master regulator of tissue repair gene expression that controls expression of PDGF, TGF-β, and other wound-healing mediators — an upstream transcriptional mechanism that amplifies the healing gene response
• VEGF-driven angiogenesis: VEGFR2 upregulation by BPC-157 potentiates angiogenic signaling, promoting new blood vessel formation at repair sites and directly improving the vascular infrastructure for healing — a mechanism operationally distinct from KPV’s inflammatory suppression

Gastrointestinal Cytoprotection and Brain-Gut Axis

• BPC-157’s most extensively documented preclinical efficacy is in gastrointestinal healing: acceleration of gastric ulcer healing, protection against NSAID-induced GI damage, resolution of experimental inflammatory bowel lesions, and acceleration of intestinal anastomosis healing across multiple animal model paradigms
• BPC-157 acts on the brain-gut axis — the bidirectional neuroenteric communication system linking the CNS to the GI tract — through modulation of serotonin and dopamine neurotransmission, vagal nerve signaling, and enteric nervous system activity; this neurological dimension extends BPC-157’s GI cytoprotective activity beyond purely structural mucosal effects
• Gastric acid independence: BPC-157 has been shown to protect GI mucosa from both acid-dependent and acid-independent injury mechanisms, making it relevant across a broader spectrum of GI pathology than acid-suppressive therapies
• Systemic cytoprotection: Beyond the GI tract, BPC-157’s repair mechanisms extend to musculoskeletal tissue (bone, tendon, ligament, muscle), neurological tissue (peripheral nerve, spinal cord), and vascular endothelium — the broadest organ-system cytoprotective profile of the two GLOW components

Oral and Injectable Bioavailability

• BPC-157’s gastric juice stability — the property that inspired its original derivation from gastric BPC — makes it suitable for oral administration to target GI-specific effects; systemic effects (musculoskeletal, neurological) are better served by subcutaneous injection
• At the 10 mg dose in this formulation, subcutaneous injection is the standard route for systemic tissue repair applications

Component 2: KPV (Lys-Pro-Val) — 10 mg

KPV is a synthetic tripeptide corresponding to the C-terminal three amino acids (positions 11–13) of alpha-melanocyte-stimulating hormone (α-MSH) — Lysine-Proline-Valine — with a molecular formula of C₁₅H₂₉N₅O₄ and molecular weight of 343.43 g/mol. KPV was identified through systematic structure-activity dissection of α-MSH’s biological activities, establishing that the C-terminal tripeptide retains the parent hormone’s full anti-inflammatory potency while completely lacking α-MSH’s melanotropic (pigmentation-stimulating) receptor binding — making KPV a pure, highly targeted anti-inflammatory melanocortin fragment with no pigmentation side effects.

NF-κB Pathway Inhibition — Core Anti-inflammatory Mechanism

KPV’s dominant and best-characterized mechanism is direct, intracellular inhibition of the NF-κB signaling pathway — the master transcription factor controlling expression of pro-inflammatory cytokines across essentially all immune and epithelial cell types:

• Inhibition of p65 RelA nuclear translocation: KPV blocks import of the p65 NF-κB subunit from the cytoplasm into the cell nucleus, preventing transcription of NF-κB-regulated inflammatory genes including TNF-α, IL-1β, IL-6, IL-8, and COX-2 — the principal mediators of acute and chronic inflammatory tissue damage
• IκBα stabilization: KPV reduces degradation of the inhibitory IκBα protein that sequesters NF-κB in the cytoplasm, providing a second convergent point of upstream pathway inhibition
• MAP kinase cascade suppression: KPV additionally suppresses MAP kinase (MAPK) inflammatory signaling — including ERK, p38, and JNK pathways — providing a second independent anti-inflammatory axis beyond NF-κB, as confirmed in intestinal epithelial cell studies
• This dual-pathway suppression (NF-κB + MAPK) distinguishes KPV from single-pathway NF-κB inhibitors and contributes to its broad efficacy across diverse inflammatory cell types

PepT1 Transporter-Mediated Intracellular Gut Delivery

KPV’s most pharmacologically distinctive feature — and the primary mechanistic rationale for its inclusion in a GI-targeted formulation — is its active intracellular transport via the PepT1 (SLC15A1) di/tripeptide transporter expressed on intestinal epithelial cells:

• PepT1 transports KPV directly inside intestinal epithelial cells lining the GI tract, delivering the peptide to its intracellular NF-κB target without requiring systemic circulation for GI-targeted activity
• This intracellular delivery route means KPV suppresses NF-κB from within the inflamed epithelial cells themselves — a mechanistic efficiency that contrasts with anti-inflammatory drugs acting on extracellular receptors and makes KPV particularly well-suited to direct GI epithelial inflammation
• PepT1 expression is upregulated in inflamed intestinal tissue (as occurs in Crohn’s disease, ulcerative colitis, and other IBD conditions) — creating a self-amplifying delivery mechanism in the precise tissue environment where KPV’s anti-inflammatory activity is most needed
• BPC-157 synergy via inflammation reduction: By suppressing the NF-κB/MAPK inflammatory cascade that drives tissue destruction, KPV directly improves the repair environment in which BPC-157 operates — reducing ongoing inflammatory damage to the tissue architecture BPC-157 is rebuilding; this is the core mechanistic rationale for the combination

MC3R Agonism — Receptor-Mediated Systemic Anti-inflammatory Activity

Beyond its intracellular PepT1-delivered mechanism, KPV also activates melanocortin-3 receptor (MC3R) in airway epithelium and immune cells through partial receptor agonism:

• MC3R activation drives anti-inflammatory cAMP/PKA signaling in macrophages and epithelial cells, complementing the intracellular NF-κB inhibition with a receptor-mediated anti-inflammatory signal at the cell surface
• MC3R is expressed across systemic immune cell populations, extending KPV’s anti-inflammatory activity beyond the GI tract to systemic inflammatory contexts — joints, skin, respiratory tissue, and other sites of chronic inflammation
• No MC1R activity: KPV does not activate MC1R (the pigmentation receptor) at therapeutic doses; none of the melanotropic adverse effects (mole darkening, skin pigmentation changes, melanoma concerns) associated with Melanotan II and α-MSH apply to KPV

Gut Barrier Integrity and Microbiome Modulation

• KPV promotes maintenance and restoration of intestinal tight junction protein expression (ZO-1, occludin, claudins), reducing intestinal permeability (“leaky gut”) and preventing pathological translocation of luminal bacteria and endotoxins into systemic circulation
• Microbiome balance: Preclinical IBD models suggest KPV administration is associated with preservation of beneficial intestinal microbial populations and attenuation of dysbiosis-driven inflammatory signaling — an emerging dimension of KPV’s gut-protective biology
• Inflammation-induced intestinal permeability and dysbiosis are each resolved by KPV’s combined barrier-reinforcing and anti-inflammatory activity — addressing both the cause and consequence of chronic GI inflammatory dysfunction

Sequential Mechanism Logic in the BPC-157/KPV Combination

The BPC-157/KPV pairing is uniquely logical from a tissue repair biology perspective:

1. KPV suppresses NF-κB/MAPK inflammation → reduces production of tissue-destructive cytokines (TNF-α, IL-1β) → attenuates ongoing structural tissue damage → creates a lower-inflammation repair environment
2. BPC-157 upregulates eNOS, VEGFR2, EGF-R, Egr-1 → drives angiogenesis, mucosal blood flow, and fibroblast proliferation → rebuilds the structural tissue architecture in the environment KPV has pacified
3. KPV’s gut barrier reinforcement and BPC-157’s mucosal cytoprotection both converge at the intestinal epithelium — addressing GI inflammation and structural mucosal integrity from two mechanistically independent angles simultaneously

The BPC-157/KPV combination benefits from rich preclinical evidence for both individual components and a pharmacologically coherent mechanistic rationale for their combination — but faces the same fundamental limitation as most peptide combinations: no published controlled human clinical trial data for the combination at any dose or ratio exists as of May 2026. BPC-157 has the most extensive preclinical evidence base of the two; KPV has stronger mechanistic specificity for the GI anti-inflammatory indication. Neither has a completed, published human RCT.

BPC-157 Research Evidence

Sikiric P, et al. (University of Zagreb, 1990s–2025): The dominant source of BPC-157’s published preclinical evidence — over 100 animal model studies demonstrating effects on GI healing, tendon and ligament repair, bone healing, muscle repair, neurological protection, and systemic anti-inflammatory activity. The concentration of this evidence in a single research group limits independent replication, and peer reviewers including McGill University’s Office for Science and Society have explicitly noted this limitation.

Emerging Journal of Orthopaedic Sports Medicine review (SAGE Journals, 2025): A systematic review of BPC-157 in orthopedic sports medicine, published in 2025, found that BPC-157 promotes healing by boosting growth factors and reducing inflammation — concluding potential utility for musculoskeletal injury while explicitly acknowledging concerns about unregulated production and lack of clinical safety data in humans.

GI healing animal evidence highlights:

• Gastric ulcer healing acceleration across NSAID-induced, stress-induced, and surgically created ulcer models
• Resolution of experimental colitis in dextran sulfate sodium (DSS) and TNBS-induced models
• Intestinal anastomosis healing improvement — clinically relevant to surgical GI repair
• Protection against gastric damage from ethanol, cysteamine, and other GI toxins

Human case reports (2025): McGill University’s Office for Science and Society noted in a 2026 review that Sikiric’s group reported in 2025 that intravenous BPC-157 was well-tolerated in two women — the only published human safety data for BPC-157 as of May 2026; the study was not a randomized controlled trial and involved only two subjects.

ClinicalTrials.gov registration (NCT07437547, February 2026): A Phase 2 trial evaluating BPC-157 for acute hamstring muscle strain injury was registered — representing the earliest formal initiation of a controlled human clinical trial for BPC-157 in the published trial registry. No results are available.

KPV Research Evidence

Catania A, et al. (Inflammatory Bowel Diseases, 2009): The foundational preclinical efficacy study for KPV in IBD models — demonstrating significant reduction in TNF-α, IL-1β, and IL-6 in colonic tissue and preservation of crypt architecture in experimental colitis, establishing the primary preclinical rationale for KPV’s GI anti-inflammatory application.

NF-κB and MAP kinase in vitro characterization: Multiple cell culture studies in intestinal epithelial cell lines (Caco-2, HT-29) and macrophage models have confirmed KPV’s dose-dependent dual suppression of NF-κB and MAP kinase inflammatory pathways, characterizing the molecular mechanism and establishing the concentration-response relationship for intracellular anti-inflammatory activity.

Taylor AW & Namba K. (American Journal of Physiology — Lung Cell and Molecular Physiology, 2012): Confirmed KPV suppresses NF-κB signaling in airway epithelium via MC3R activation — validating the receptor-dependent component of KPV’s systemic anti-inflammatory mechanism and extending its relevance beyond GI tissue.

PepT1 transporter delivery studies: Research published in Journal of Pharmaceutical Sciences characterized KPV’s transdermal iontophoretic and enteric delivery properties via the PepT1 transporter — mechanistic delivery research confirming the intracellular gut epithelial targeting that is central to KPV’s GI anti-inflammatory rationale.

Corneal wound healing (in vitro, multiple studies): KPV demonstrated increased cell viability and accelerated wound closure in rabbit corneal epithelial models — extending its tissue-protective profile beyond GI tissue to epithelial healing generally.

Human clinical data: As of May 2026, no completed, published randomized controlled trial of KPV in human subjects exists. No Phase 1 human safety trial for KPV has been published. KPV has no registered ClinicalTrials.gov entry as of May 2026.

Evidence Comparison Table

Clinical Development

No active FDA-registered clinical development program exists for a BPC-157/KPV combination product as of May 2026:

• BPC-157: One gov registration (NCT07437547) for musculoskeletal injury — the earliest formal human trial initiation; no GI-indication trial registered
• KPV: No registered clinical trial in any jurisdiction as of May 2026 — the earliest-stage compound in the combination from a clinical development standpoint
• No sponsor has filed an IND, NDA, or BLA for any BPC-157/KPV combination product with the FDA

Regulatory Status

FDA (United States) — Identical Regulatory Position for Both Components:

Both BPC-157 and KPV occupy the same regulatory position as of May 2026 — a situation distinct from the KLOW and GLOW formulations where component statuses differed:

• Both compounds were placed on the FDA’s Category 2 bulk drug substance list in September 2023, explicitly restricting their use in 503A and 503B compounding
• Both compounds were removed from Category 2 effective April 23, 2026, following withdrawal of the original nominations — consistent with the broader FDA peptide reclassification wave driven by the RFK Jr./MAHA regulatory environment
• Neither compound has been placed on Category 1 (503A eligible substances); both remain in a regulatory gray zone — no longer explicitly prohibited but not yet formally authorized for compounding
• PCAC review for both compounds is scheduled for July 23–24, 2026; the Pharmacy Compounding Advisory Committee will evaluate whether BPC-157 and KPV should be recommended for Category 1 listing; PCAC recommendations are non-binding and formal rulemaking follows
• The FDA Law Blog has explicitly noted that removal from Category 2 is a process step, not a compounding clearance — prescribing or compounding BPC-157 or KPV as of May 2026 remains legally uncertain
• Neither compound is FDA-approved for any indication; neither is listed in USP or NF monographs; neither is a component of any FDA-approved drug product

Key Post-PCAC Regulatory Scenarios (July 2026):

WADA (Anti-Doping): Both BPC-157 and KPV are prohibited in competitive sport under the 2026 WADA Prohibited List (effective January 1, 2026):

• BPC-157: Prohibited under S0 (Non-Approved Substances) — no approved therapeutic use in any jurisdiction globally; explicitly identified in USADA and US Department of Defense anti-doping advisories as a prohibited substance
• KPV: Prohibited under S0 (Non-Approved Substances) — no approved therapeutic use in any jurisdiction globally
• WADA’s S0 prohibition applies regardless of the athlete’s intent, the route of administration, or the dose — including oral BPC-157 taken for purported GI health purposes
• No therapeutic use exemption (TUE) pathway exists for either compound; any athlete subject to anti-doping rules who uses this combination faces a potential anti-doping rule violation

International:

• EMA (EU): No approved status for either compound
• TGA (Australia): No approved status; peptide product restrictions apply broadly
• Health Canada / PMDA (Japan): No approved status for either compound
• Both compounds are available through unregulated research chemical vendors and some oral supplement formulations (marketed under names such as “Guttides”); none of these products operate under cGMP oversight applicable to injectable human-use products

The safety profile of the BPC-157/KPV combination must be assessed both by individual component and by combination. Both compounds have the same fundamental limitation: no controlled human safety trial has been published for either compound. BPC-157 has the broader preclinical safety record and a 2025 case report of IV tolerability; KPV’s safety characterization is limited to in vitro cytotoxicity data and animal model tolerability. The combination’s safety profile has not been evaluated in any controlled study.

BPC-157 Safety Profile

From animal studies and case report surveillance:

• Animal studies across multiple species characterize BPC-157 as well-tolerated at studied doses (typically 2–10 mcg/kg in rodents) with no observable toxicity in acute and sub-chronic exposure paradigms; dose extrapolation to the 10 mg flat dose in this formulation requires significant caution
• 2025 human case report: Sikiric’s group reported that intravenous BPC-157 was well-tolerated in two women with no observed adverse effects — the entirety of the controlled human safety record as of May 2026; this is not a dose-ranging or Phase 1 safety trial and cannot be generalized to broader populations or dose levels
• Theoretical oncological concern: BPC-157’s pro-angiogenic mechanisms (VEGFR2 upregulation, NO-driven vascularization) raise a theoretical risk of tumor promotion in patients with pre-existing malignancy; this risk has not been evaluated in any human study; current animal data and preliminary clinical observation do not demonstrate a direct tumor-promoting signal
• Drug interactions: BPC-157’s NO-pathway modulation may interact with vasodilatory agents, antihypertensives, and PDE5 inhibitors; the clinical significance has not been formally evaluated
• Manufacturing risk: BPC-157 produced through unregulated research chemical vendors — the predominant current supply chain — carries contamination risks (TFA, endotoxins, heavy metals, microbial load) that cannot be mitigated without cGMP manufacturing oversight

KPV Safety Profile

From in vitro and animal data (no human data):

• Cell viability studies in intestinal epithelial and corneal epithelial models characterize KPV as non-cytotoxic at concentrations up to 10 μM — the primary in vitro safety dataset
• Animal IBD models report no observed adverse effects at therapeutically relevant doses
• No melanotropic effects: KPV produces no MC1R-mediated pigmentation changes; mole darkening, skin pigmentation, and melanoma-related risks of Melanotan II and α-MSH do not apply — a safety advantage within the melanocortin peptide class
• Immunosuppressive risk at high doses: NF-κB and MAPK suppression across immune cell types is KPV’s primary anti-inflammatory mechanism; chronic or high-dose systemic suppression of these pathways could theoretically impair acute immune responses to infection, vaccination, or wound healing; this risk is uncharacterized in human subjects
• No Phase 1 human safety data published — the most significant safety limitation; all characterization is from non-human models

Combination Safety Considerations

• No human combination safety data: No controlled study has evaluated the pharmacokinetic interaction, additive adverse effects, or immune response profile of BPC-157 + KPV at any dose ratio
• Additive anti-inflammatory convergence: Both BPC-157 (via indirect anti-inflammatory effects through tissue repair and NO pathways) and KPV (via direct NF-κB/MAPK suppression) reduce inflammatory signaling; the combined degree of inflammation suppression may be greater than either component alone — potentially impairing acute immune responses at high doses
• Additive pro-angiogenic activity: BPC-157’s VEGFR2/eNOS-driven angiogenesis in the context of KPV’s reduced inflammatory inhibition of blood vessel growth creates a favorable healing environment in normal tissue — but represents an uncharacterized risk in patients with occult malignancy, proliferative diabetic retinopathy, or other angiogenesis-sensitive pathologies

Oral vs. injectable route distinction: BPC-157 in oral form (capsules/sublingual) delivers GI-targeted cytoprotection with a substantially lower systemic safety risk than injectable formulations; KPV oral delivery via PepT1 transporter is mechanistically well-suited to GI-targeted administration — both compounds’ GI-specific applications may be achievable with oral routes, reducing the immunogenicity and injection-site risks of injectable administration

1. Sikiric P, et al. (1993 onward). BPC-157 research program — comprehensive publication list. University of Zagreb, Department of Pharmacology. Summary reviews in Current Pharmaceutical Design and Journal of Physiology — Paris. https://pubmed.ncbi.nlm.nih.gov/
2. Sikiric P, et al. (2016). Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications. Current Neuropharmacology, 14(8), 857–865. https://pmc.ncbi.nlm.nih.gov/articles/PMC5333585/
3. Emerging review: BPC-157 in Orthopaedic Sports Medicine. SAGE Journals — Orthopaedic Journal of Sports Medicine, 2025. https://journals.sagepub.com/doi/abs/10.1177/15563316251355551
4. Catania A, et al. (2009). Melanocortin-derived tripeptide KPV has anti-inflammatory effects in models of IBD. Inflammatory Bowel Diseases, 15(5), 738–748.
5. Taylor AW & Namba K. (2012). Mechanism of KPV action and a role for MC3R agonists in airway epithelial inflammation. American Journal of Physiology — Lung Cell and Molecular Physiology, 303(3), L223–L232. https://pmc.ncbi.nlm.nih.gov/articles/PMC3403564/
6. Superpower Health. (2026, April 23). KPV Peptide: Benefits, Uses, and What the Research Shows — regulatory status update. https://superpower.com/guides/kpv-peptide-benefits
7. Superpower Health. (2026, April 22). Peptides for Gut Health: Evidence-Based Options — BPC-157 and KPV regulatory and mechanism analysis. https://superpower.com/guides/peptides-for-gut-health
8. Laser Skin Solutions. (2025). The Benefits of Peptides: BPC-157 & KPV for Healing and Gut Health. https://www.laserskinsolutions.com/blog/the-benefits-of-peptides-bpc157-kpv-for-healing-and-gut-health/
9. McGill University Office for Science and Society. (2026, March). BPC-157 — No Proof Required! https://www.mcgill.ca/oss/article/medical-critical-thinking-health-and-nutrition-contributors/body-protection-compound-no-proof-
10. USADA / OPSS. (2025). BPC-157: A prohibited peptide and an unapproved drug found in health and wellness products. https://www.opss.org/article/bpc-157-prohibited-peptide-and-unapproved-drug-found-health-and-wellness-products
11. S. Food and Drug Administration. (2026, May). Bulk Drug Substances Nominated for Use in Compounding Under Section 503A — Updated Category List. https://www.fda.gov/media/94155/download
12. The FDA Law Blog. (2026, April 20). FDA’s Pep(tide) Rally! What Compounders and Industry Need to Know. https://www.thefdalawblog.com/2026/04/fdas-peptide-rally-what-compounders-and-industry-need-to-know-post-1-of-2/
13. BioPharma Dive. (2026, April 15). FDA moves toward easing restrictions on certain peptides. https://www.biopharmadive.com/news/fda-peptides-rfk-advisory-committee-restrictions/817685/
14. World Anti-Doping Agency. (2025). 2026 WADA Prohibited List — S0 Non-Approved Substances (effective January 1, 2026). https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
15. ClinicalTrials.gov. (2026). BPC-157 for Acute Hamstring Muscle Strain Repair. NCT07437547. https://clinicaltrials.gov/study/NCT07437547